AstraZeneca and Daiichi's Datroway offered significant improvements to overall survival (OS) in immunotherapy-ineligible patients.
Cellectar Biosciences (CLRB) announced that after a scientific advice procedure, the Scientific Advice Working Party of the European Medicines Agency advised that filing for a Conditional Marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback